SynthesisFrontiers in oncology2025
Inverse association between serum lipid profiles and hepatocellular carcinoma risk: a meta-analysis of epidemiological studies.
Synthesis in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Review
- Article
- Subgroup-Specific Nomogram for Refined Risk Stratification in Hepatocellular Carcinoma Patients with Low LDL-C.Journal of hepatocellular carcinoma · 2026Article
- Polyunsaturated fatty acids as a potential preventive and therapeutic intervention for metabolic dysfunction-associated steatotic liver disease and its progression to hepatocellular carcinoma.Frontiers in nutrition · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The relationship between serum lipid profiles and hepatocellular carcinoma (HCC) risk remains controversial. We aimed to clarify this association through a systematic meta-analysis of epidemiological studies. Methods: A systematic literature search was conducted in PubMed, Embase, and Web of Science (2000-May 2023) for prospective, retrospective, and cross-sectional studies reporting adjusted risk estimates (HR/OR) of HCC associated with serum lipids. Pooled effect sizes were calculated using random-effects models, with heterogeneity assessed via Cochran's Q and I² statistics. Results: Twenty-three studies (16 cohorts, 7 case-control) involving 1.2 million participants ((including both healthy individuals and patients with chronic liver diseases)) were included. Elevated serum total cholesterol (TC) was inversely associated with HCC risk (HR = 0.71, 95% CI: 0.64-0.78; I²=0%). Similar protective effects were observed for high LDL (HR = 0.46, 95% CI: 0.36-0.59; I²=97%), triglycerides (HR = 0.79, 95% CI: 0.62-0.99; I²=94%), and dyslipidemia (HR = 0.64, 95% CI: 0.50-0.83; I²=81%). No significant association was found for high-density lipoprotein (HDL). Sensitivity analyses confirmed robustness for TC and LDL, while TG results were influenced by a single study. Conclusion: This meta-analysis provides robust evidence that elevated serum cholesterol and specific lipid subfractions are associated with reduced HCC risk. Further mechanistic studies are warranted to elucidate the role of lipid metabolism in hepatocarcinogenesis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.